RALEIGH, N.C.--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Gastrointestinal Drugs Advisory Committee of the FDA supports the Salix/FDA developed proposed design of a clinical trial to evaluate the safety, efficacy and durability of response with repeat treatment cycles of XIFAXAN® (rifaximin) for irritable bowel syndrome with diarrhea (IBS).
